The company and its Research & Development activities to tackle antimicrobial resistance, infectious and respiratory disease was highlighted in a recent report by Healthcare UK,  a joint initiative of the Department of Health and Social Care, NHS England and the...

Innovative biotechnology group company NovaBiotics has confirmed that NovaBiotics and NovaBiotics Consumer Health will move into ONE BioHub in Aberdeen. Full details are available here ONE News

NovaBiotics Consumer Health Limited (“NCH”), a division of NovaBiotics Limited (“NovaBiotics” or “the Company”), today announced that it has entered into a distribution agreement with Brand Creations Limited (“BCL, for the rights to commercialise and distribute...

The Institute of Podiatrists (IOP) successfully launched our next-generation personal care nail health system on their stand at the Primary Care Show, May 15th-16th.  The IOP will also showcase this highly innovative product at FootHealth 2024, June 3rd-4th.  These...

ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...

Publication of NovaBiotics’ research on the host-mediated anti-viral (including against coronaviruses and influenza) and anti-inflammatory mechanism of action of cysteamine, the active component of its advanced clinical stage NM001 and NM002 product candidates for...

NovaBiotics adds ISO 14001: 2015 and ISO 45001: 2018 accreditations to its integrated quality management system. ISO 14001: 2015 Environmental Management Systems and ISO 45001:2018 Occupational Health & Safety Systems accreditation have now been awarded to...

New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...

Aberdeen, January 4, 2022 -  NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Dr Deborah O’Neil OBE, FRSE, Chief Executive Officer of NovaBiotics,...

NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...